Total
0
Shares
Emerald Clinics (ASX:EMD) - Managing Director & CEO, Michael Winlo - The Market Herald
Managing Director & CEO, Michael Winlo
Source: WA Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Emyria (EMD) has added a second Emerald Clinic consulting suite in Perth due to strong growth
  • The company says the expansion comes off the back of record patient appointments in January 2021 and the recent growth in Victoria
  • The new Perth suite will have the capacity for four additional consulting rooms
  • Additionally, the new clinic will also support the clinical trials being planned for Emyria’s first drug development program, EMD-003
  • On market close for the day, Emyria is down 2.56 per cent and trading at 19 cents per share

Emyria (EMD) has added a second Emerald Clinic consulting suite in Perth due to strong growth.

The company says the expansion comes off the back of record patient appointments in January 2021 and the recent growth in Victoria.

The new Perth suite will have the capacity for four additional consulting rooms and is co-located within the site of West Leederville Private Hospital complex.

Additionally, the new clinic will also support the clinical trials being planned for Emyria’s first drug development program, EMD-003, targeting unmet needs in
mental health.

EMD-003 is the company's first cannabinoid-based medicine, which Emyria is aiming to have Australia's Therapeutic Goods Administration approve.

"Western Australia was the first Emerald Clinics location. Demand for our services from both patients and referring doctors has grown every month since we opened," Managing Director Michael Winlo said.

"We anticipate this expansion will allow us to improve our waiting times and see more patients which, in turn, improves our proprietary data asset," he added.

Notably, this expansion has the potential to double the capacity of Perth.

On market close for the day, Emyria is down 2.56 per cent and trading at 19 cents per share.

EMD by the numbers
More From The Market Herald
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" TGA fast tracks evaluation of Telix Pharmaceuticals’ (ASX:TLX) cancer imaging product

The Theraputic Goods Administration (TGA) has commenced a priority evaluation process for Telix Pharmaceuticals’ (TLX) prostate cancer imaging product, Illuccix.
Pharmaxis (ASX:PXS) - CEO, Gary Phillips (left) - The Market Herald

" Pharmaxis (ASX:PXS) to raise $4.4M via placement

Pharmaxis (PXS) has received firm commitments to raise $4.4 million through a placement.
Universal Biosensors (ASX:UBI) - CEO, John Sharman - The Market Herald

" Universal Biosensors (ASX:UBI) toasts new distribution agreement for wine testing device

Universal Biosensors (UBI) has entered into a non-exclusive agreement with Singularity SpA to distribute its wine testing platform device in Chile.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" Paradigm Biopharmaceuticals (ASX:PAR) enrols first participant in osteoarthritis trial

Paradigm Biopharmaceuticals (PAR) has enrolled its first patient in its knee osteoarthritis (OA) biomarker study in Box Hill, Victoria.